XSNX 0.01 0.00 0.00%
Menu
XSNX 0.01 0.00 0.00%
Menu
Recent advances in cellular technologies allowed our quantum leap in discovery speed and implementation of personalized cancer and neurological diagnostics and immunotherapeutics.
Our patented technology, TLR-AD1 is a novel, highly-focused immunotherapeutic approach to better equip the patient’s own immune cells to recognize and kill cancer cells.
StemVax Therapeutics has a novel immunotherapeutic approach to treat brain tumor patients with Glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient’s tumor. Our platform technology focuses on enhancing the patient’s immune cells to fight their unique cancer by utilizing the antigens specific to the patient’s tumor.
Our unique combination of TLR adjuvants, in addition to the tumor’s antigens, obtained from the patient, promotes an enhanced immune response shown to be more efficacious in pre-clinical studies when compared to previous generations of the therapy. TLR-AD1 therapy is at the Investigational New Drug (IND) filing stage and StemVax Therapeutics seeks to start human clinical trials after obtaining IND approval. TLR-AD1 is investigational and not approved anywhere globally. Its efficacy and safety in humans have not been established.
stemvax.com
We are utilizing novel immunotherapy approaches to enhance the patient’s own immune cells to recognize and kill cancer cells. We also seek to improve our ability to detect cancer earlier and more accurately. Together, we are developing technology that utilizes artificial intelligence platforms to provide better personalized and patient-centered care.
StemVax Therapeutics has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient’s tumor. Our platform technology focuses on enhancing the patient’s immune cells to fight their unique cancer by utilizing the antigens specific to the patient’s tumor. Our unique combination of TLR adjuvants, in addition to the tumor’s antigens, obtained from the patient, promotes an enhanced immune response shown to be more efficacious in pre-clinical studies when compared to previous generations of the therapy. TLR-AD1 therapy is at the Investigational New Drug (IND) filing stage and StemVax Therapeutics seeks to start human clinical trials after obtaining IND approval.
Revolutionary advances in the understanding of how our bodies can fight cancer, and how to put that information to use in treating existing tumors. NovAccess Global’s team of experts is working to strengthen the capability of the human body’s defense against cancer.
Stay up-to-date with our journey
